Autoimmune Cytopenia and BcR Inhibitors

ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)

NCT06378138 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction

NCT03734198 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Ibrutinib in Previously Untreated Binet Stage a Chronic Lymphocytic Leukemia with Risk of Disease Progression

NCT02863718 ·Status: COMPLETED ·Phase: PHASE3

A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT01578707 ·Status: COMPLETED ·Phase: PHASE3

Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia

NCT01294618 ·Status: COMPLETED ·Phase: PHASE2

ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

NCT02787369 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT01724346 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation

NCT00219726 ·Status: COMPLETED ·Phase: PHASE2

Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL

NCT05694312 ·Status: RECRUITING ·Phase: PHASE2

Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

NCT02437019 ·Status: APPROVED_FOR_MARKETING

A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

NCT04694560 ·Status: WITHDRAWN

A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia

NCT02251548 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in Children

NCT00287105 ·Status: COMPLETED ·Phase: PHASE2

Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia

NCT00281918 ·Status: COMPLETED ·Phase: PHASE3

Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia

NCT02388048 ·Status: COMPLETED ·Phase: PHASE2

Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant

NCT03267186 ·Status: COMPLETED ·Phase: PHASE2

Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients

NCT01862445 ·Status: UNKNOWN

Efficacy and Toxicity of Blinatumomab in the French ATU for Adult BCP-ALL R/R, or With MRD+ (FRENCH-CYTO)

NCT03751072 ·Status: COMPLETED

Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab

NCT01123356 ·Status: COMPLETED ·Phase: PHASE2

Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL

NCT01722487 ·Status: COMPLETED ·Phase: PHASE3

A Study of BNC105P Combined With Ibrutinib

NCT03454165 ·Status: COMPLETED ·Phase: PHASE1

Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)

NCT03207555 ·Status: COMPLETED ·Phase: PHASE2

A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT

NCT03912064 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

A Long-term Extension Study of PCI-32765 (Ibrutinib)

NCT01804686 ·Status: RECRUITING ·Phase: PHASE3

Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia

NCT04657094 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2